These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16838889)

  • 1. Pompe disease therapy presents coverage challenge.
    Morrow T
    Manag Care; 2006 Jun; 15(6):63-4. PubMed ID: 16838889
    [No Abstract]   [Full Text] [Related]  

  • 2. Enzyme replacement in Pompe disease with an alpha-glucosidase-low density lipoprotein complex.
    Williams JC; Murray AK
    Birth Defects Orig Artic Ser; 1980; 16(1):415-23. PubMed ID: 7004520
    [No Abstract]   [Full Text] [Related]  

  • 3. Enzyme replacement for infantile Pompe disease: the first step toward a cure.
    Wagner KR
    Neurology; 2007 Jan; 68(2):88-9. PubMed ID: 17210887
    [No Abstract]   [Full Text] [Related]  

  • 4. First treatment for Pompe disease.
    FDA Consum; 2006; 40(4):3. PubMed ID: 17245826
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA approves new treatment for late-onset Pompe disease.
    Home Healthc Nurse; 2010 Sep; 28(8):457. PubMed ID: 20811179
    [No Abstract]   [Full Text] [Related]  

  • 6. Pompe disease in infants and children.
    Kishnani PS; Howell RR
    J Pediatr; 2004 May; 144(5 Suppl):S35-43. PubMed ID: 15126982
    [No Abstract]   [Full Text] [Related]  

  • 7. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
    Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-glucosidase (CHO) (Genzyme).
    Lachmann RH
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1101-10. PubMed ID: 15535432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.
    Ing RJ; Cook DR; Bengur RA; Williams EA; Eck J; Dear Gde L; Ross AK; Kern FH; Kishnani PS
    Paediatr Anaesth; 2004 Jun; 14(6):514-9. PubMed ID: 15153218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA balks at Myozyme scale-up.
    Mack G
    Nat Biotechnol; 2008 Jun; 26(6):592. PubMed ID: 18536660
    [No Abstract]   [Full Text] [Related]  

  • 12. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.
    Hunley TE; Corzo D; Dudek M; Kishnani P; Amalfitano A; Chen YT; Richards SM; Phillips JA; Fogo AB; Tiller GE
    Pediatrics; 2004 Oct; 114(4):e532-5. PubMed ID: 15466083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desensitisation of the youngest patient with Pompe disease in response to alglucosidase alfa.
    Karagol IH; Bakirtas A; Yilmaz O; Topal E; Kucukcongar A; Ezgu FS; Demirsoy MS; Turktas I
    Allergol Immunopathol (Madr); 2014; 42(4):372-5. PubMed ID: 23769736
    [No Abstract]   [Full Text] [Related]  

  • 14. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
    Katzin LW; Amato AA
    J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.
    Ravaglia S; Danesino C; Pichiecchio A; Repetto A; Poloni GU; Rossi M; Fratino P; Moglia A; Costa A
    Adv Ther; 2008 Aug; 25(8):820-9. PubMed ID: 18704279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease.
    Drost MR; Schaart G; van Dijk P; van Capelle CI; van der Vusse GJ; Delhaas T; van der Ploeg AT; Reuser AJ
    Muscle Nerve; 2008 Feb; 37(2):251-5. PubMed ID: 17894362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment antibodies against acid α-glycosidase in a patient with late-onset Pompe disease.
    Papadopoulos C; Papadimas GK; Spengos K; Manta P
    Muscle Nerve; 2012 Mar; 45(3):452. PubMed ID: 22334186
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series.
    Wang LY; Ross AK; Li JS; Dearmey SM; Mackey JF; Worden M; Corzo D; Morgan C; Kishnani PS
    Paediatr Anaesth; 2007 Aug; 17(8):738-48. PubMed ID: 17596219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alglucosidase alfa and Pompe disease: still going strong?
    Lipinski SE
    Mol Genet Metab; 2012 Nov; 107(3):245-6. PubMed ID: 23034445
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
    Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
    Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.